Adaptation of Salmonella enterica to antibiotics and innate immunity effectors by Vestö, Kim
From Department of Microbiology, Tumor and Cell Biology 
Karolinska Institutet, Stockholm, Sweden 
ADAPTATION OF SALMONELLA 








All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB, 2021 




Adaptation of Salmonella enterica to antibiotics and 
innate immunity effectors 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.)  
By 
Kim Vestö 
The thesis will be defended in public at lecture hall CMB, Berzelius väg 21, Solna  
 




Professor Mikael Rhen 
Karolinska Institutet 




Senior researcher Edmund Loh 
Karolinska Institutet 




Associate professor Lotte Jelsbak 
Roskilde University 
Department of Science and Environment 
 
Examination Board: 
Associate professor Peter Bergman 
Karolinska Institutet 
Department of Laboratory Medicine 
 
Associate professor Elena Vikström 
Linköpings Universitet 
Department of Biomedical and Clinical Sciences 
 
Associate professor Anna Smed-Sörensen 
Karolinska Institutet 









POPULAR SCIENCE SUMMARY OF THE THESIS 
Bacteria are of extreme importance for the planet and humanity. Most bacteria are 
harmless and are part in various activities ranging from helping plants to grow to 
breaking down our food in our intestines. However, a handful of bacteria are not 
harmless and will cause an infection if they get access to the human body. Some of 
these infections are very serious as exemplified by bacterial growth in the lungs or 
the urinary tract, which can even allow for bacteria to enter the blood and possibly 
lead to death of the infection person. When one is unfortunate enough to experience 
a serious bacterial infection one can usually find help in antibiotics. Antibiotics are 
medicines that are designed to kill bacteria or stop bacteria from growing, which is 
how they work as treatment for infections. However, the consequence of extensive 
use of antibiotics can lead to bacteria becoming resistant to antibiotics. This means 
that if one gets and infection caused by a resistant bacteria, the bacteria will not be 
affected when given antibiotic treatment.  
This is exactly what has happened with many infections today, leaving very few 
treatment options left. One such infection is called typhoid fever which is caused by a 
bacterium called Salmonella. Typhoid fever is most common in low- and 
middle-income countries in Africa and Asia and one gets it by eating or drinking the 
food that has been contaminated with the bacterium. After this Salmonella will enter 
the body and make its way to the liver, spleen and bone marrow. This makes the 
person very ill and can even lead to death. In order to find new treatments to the 
infections Salmonella cause one has to gain knowledge about the biology of the 
bacterium by for example studying antibiotic resistance or the ability of the bacterium 
to grow within cells. This is analogous to the fact that if your car breaks down it will 
be very hard for you to fix it if you don't understand how the motor of the car works. 
For this in this thesis I have studied a variant of Salmonella that does not cause 
typhoid fever in humans, but causes a typhoid fever-like illness in mice. This 
Salmonella enables easier access to experiments due to it being less dangerous 
than the variant of Salmonella that causes typhoid fever.   
As such to try to increase our knowledge about the biology of Salmonella we 
discovered a new gene involved in antibiotic resistance towards a specific antibiotic, 
namely vancomycin. This gene of Salmonella is called mepS and the protein for 
 
 
which the gene codes for functions in the turnover of the bacterial cell wall, a 
structure not existing in humans. In this we show that if one removes mepS from 
Salmonella the bacterium becomes sensitized to vancomycin. Further experiments 
confirmed that mepS was required for Salmonella to be resistant to vancomycin. In 
this way we have increased the knowledge about what is required by Salmonella to 
survive the antibiotic and possibly found a new target for future antibiotic treatment in 
the form of mepS. 
As for Salmonellas ability to grow within cells we found that a gene named prc, which 
codes for a protein whose function is to degrade other proteins, is needed for the 
bacterium to be able to fully survive. In this we also show that the importance of prc 
for growth within cells is dependent on an other gene called pbp3sal, which codes for 
a protein needed in building the cell wall when growing within mouse cells. In 
addition we show the same requirement for prc in a mouse infection model further 
highlighting the importance of Prc in Salmonellas ability to cause disease. This adds 
to our knowledge of which genes are required for Salmonellas ability to cause 
disease and suggests that the proteins in question could be targets for future 
antibiotic treatment.  
The genes needed for Salmonella to be able to grow within cells is one aspect of 
how Salmonella causes disease. An other aspect is the fact that the cells are not 
happy with Salmonella being inside them. This results in that when the cell feels that 
Salmonella has entered them it will try to kill the bacterium in many different ways. In 
this we have studied how a specific protein called iNOS works in response to a 
Salmonella infection of individual cells. The function of iNOS is to produce nitric 
oxide, a molecule that when further reacting with strong oxidants becomes very 
toxic, that will destroy various parts of the bacteria resulting in growth arrest or death. 
We find that when Salmonella has successfully grown within a cell, that cell is often 
lacking oxygen and iNOS is not present. This we suggest could be due to the 
general stress Salmonella causes to the cell when growing within it, leading to a 
reduction in protein synthesis and hence lack of iNOS. These results begin to 












Salmonella enterica is a bacterial pathogen causing major morbidity and mortality in 
low- and middle-income countries. The bacteria can cause a wide range of disease, 
ranging from the severe systemic disease typhoid fever to localized gastroenteritis. 
Characteristics of typhoid fever, caused by Salmonella enterica serovar Typhi (S. 
Typhi), include the bacteria’s ability to proliferate within host cells, intrinsic resistance 
to selected antibiotics, and emerging acquired antibiotic resistance. As S. Typhi is 
strictly human adapted and highly pathogenic one often uses Salmonella enterica 
serovar Typhimurium (S. Typhimurium) as a model organism for understanding 
details of typhoid fever. Using S. Typhimurium this thesis reveals genetic details 
governing intrinsic antibiotic resistance and virulence in in vitro and in vivo infection 
models, as well as details the interplay between the pathogen and phagocytic cells.  
In this we have discovered a new genetic determinant for intrinsic vancomycin 
resistance coding for muramyl endopeptidase MepS (also known as Spr), an 
enzyme tasked with cleaving cell wall, and that MepS is functionally connected to the 
periplasmic protease Prc (also known as Tsp) in this matter. Vancomycin is an 
antibiotic that inhibits cell wall synthesis, but is not effective against Gram-negative 
enteric bacteria. This has been thought to be due to the relative impermeability of the 
outer membrane resulting in vancomycin not being able to access its target the cell 
wall (due to its large size). However, we present results that adds to this in showing 
that the outer membrane is not the only factor resulting in intrinsic vancomycin 
resistance.  
With regard to intracellular pathogenesis of S. Typhimurium in mouse infection 
models we show in this thesis that the periplasmic protease Prc is required for the 
full fitness of the bacterium when in macrophages and mice. This requirement is 
dependent on the cell wall synthesizing enzyme PBP3SAL highlighting the possible 
role of Prc in regulation of bacterial proliferation during intracellular phases of 
infection. As for further aspects of intracellular pathogenesis of S. Typhimurium in 
macrophages we show that the presence of S. Typhimurium in single cells correlates 
with hypoxia and lack of iNOS, an innate immunity effector tasked with killing 
invading organisms by producing reactive nitrogen species. We suggest this 
 
 
correlation to be a result of general shut-off of protein synthesis due to hypoxia 
generated by the presence of S. Typhimurium proliferating within the macrophage. 
All these result add to the basic knowledge of both determinants for intrinsic 
antibiotic resistance and aspects governing intracellular pathogenesis of S. 
Typhimurium with regards to both genes involved and effect on innate immunity 
effectors. We believe the results presented in this thesis is a good starting point for 
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This thesis was written during the fall and winter of 2020/2021. The year 2020 will be 
remembered as the year of the SARS-CoV-2/COVID-19 pandemic. As of writing this 
it is now over a year since the first descriptions of "undiagnosed pneumonia" 
emerged from China on the 30th of December 2019, a message disseminated by 
ProMED, a surveillance system for infectious diseases. Yet it is still less than a year 
from WHO announcing the outbreak of SARS-CoV-2 being a pandemic the 11th of 
March 2020. Due to the pandemic research has come to the forefront both in media 
and in the eye of the public. In this we have seen a global response towards an 
infectious agent on a massive scale; immense investments in both treatment and 
prevention from national and private entities alike. By far the biggest achievement 
during the pandemic is the fact that the first vaccine against the disease SARS-CoV-
2 causes, i.e. COVID-19, has already gained licensure in the form of emergency use 
authorization licensure in December of 2020. This is an unbelievable achievement 
for humanity. 
However, for those who have been studying and teaching about infectious diseases 
for a big part of their academic life this achievement is slightly bittersweet. The 
reason for this comes from the fact that even though it might have seemed like 
COVID-19 was the only infectious disease in existence during 2020, this is not the 
case. Various infectious diseases have been causing a massive burden on human 
health year in, year out, even during the pandemic of 2020 and will continue to do so 
after the pandemic. Hence, a hopeful optimist might look at the response mustered 
by humanity towards the pandemic and ask "could we mobilize the same resources 
used to combat SARS-CoV-2 in order to combat other infectious diseases such as 
malaria or tuberculosis?". To this a cynic might answer "we can, we could have, we 
haven't, and we probably will not". I'm not certain whether I'm the hopeful optimist or 
the cynic, or something in between, but I hope that the pandemic of 2020 will be a 
year when we realize we really can have an impact on infectious diseases and 
reduce the mortality caused by them if we wish to do so.  
On this list of infectious diseases addressed with the same vigor as SARS-CoV-2 I 
hope to see infections caused by the bacterium Salmonella enterica. The burden of 
these infections are substantial globally and with increasing antibiotic resistance the 
 
 2 
treatment options are quickly becoming limited. This thesis aims to advance our 
understanding of fundamental aspects of antibiotic resistance and pathogenesis of 
Salmonella. This has been done by studying genetic requirements of the bacterium 
for both antibiotic resistance, intracellular pathogenesis, and adaptation to innate 





2 LITERATURE REVIEW 
2.1 Salmonella  
Salmonella is a genus of Gram-negative bacteria known to have the ability to infect 
great many species of animal with a large amount of morbidity and mortality in 
humans (1–3). The genus is further divided into two species; Salmonella bongori and 
Salmonella enterica  (S. enterica) with S. enterica being responsible for all the 
human pathology caused by the genus. The clinical manifestations of infections 
caused by different serovars of S. enterica vary a lot and can be divided into three 
distinct types of infection. These infections are typhoid fever, invasive non-typhoidal 
salmonellosis, and non-typhoidal salmonellosis all of which will be described in the 
following sections. The common denominator for all the different types of diseases 
caused by S. enterica is that they are consequences of an individual ingesting 
foodstuff or water contaminated with the bacterium. Hence, the majority of the 
burden of disease caused by S. enterica globally can mostly be attributed simply to 
the lack of clean water and sanitation as is the case for low- to middle-income 
countries (4–8). Even in countries where infrastructure for safe water and sanitation 
are more developed outbreaks of S. enterica can still arise from almost any kind of 
contaminated foodstuff ranging from eggs and seafood to ice cream and sprouts (9–
14).  
2.2 Typhoid fever 
Out of the three diseases typhoid fever is the most severe. It manifests as an 
invasive systemic disease in immunocompetent individuals with one publication 
estimating a case-fatality ratio of 0.95%, and much higher in non-treated individuals, 
resulting in a total of 135,900 deaths from 14 million cases yearly (1) with an other 
publication estimating the total number of infections to 17.8 million solely in low- and 
middle-income countries (15). However, the true nature of these numbers is hard to 
precisely estimate as highlighted by the 95%-confidence interval being 7 to 48 million 
cases annually (15). Regardless, it is well established that the highest burden of 
disease lies in central Africa and eastern/southeastern Asia with the majority of 
infection occurring in children under 5 years of age (1,15–17). The serovars of S. 
enterica causing typhoid fever are S. enterica serovar Typhi (S. Typhi), S. enterica 
serovar Paratyphi (S. Paratyphi) A, B and C, with the disease caused by the serovar 
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Paratyphi sometimes distinguished as paratyphoid fever due to them causing a 
slightly less severe disease compared to serovar Typhi (18,19). 
Once an infection with S. Typhi is initiated by ingesting the bacterium it passes 
through the esophagus into the stomach and progress towards the small intestine. 
From hereon the exact details of the pathogenesis of typhoid fever in humans are 
uncertain due to S. Typhi being human-specific pathogen. This facts makes studies 
both ethically and practically difficult to conduct.  Instead, the details of the 
pathogenesis are mostly inferred from animal models, such as mouse models, 
where a typhoid fever-like illness can be manifested using Salmonella enterica 
serovar Typhimurium (S. Typhimurium) as the model organism. In these host-
pathogen pairs of mouse and S. Typhimurium it has been shown that following entry 
into the small intestine the bacterium will adhere to the epithelial mucosa of the 
intestine (20,21). From here the bacteria will invade the host by entering intestinal 
epithelial cells (20,22,23) and/or M cells, cells part of the intestine whose function is 
to sample the lumen of the intestine (24–27), to traverse deeper into the host 
(22,28,29). 
Following traversion of the intestine through M cells Salmonella will be within Peyer's 
patches, an immune organ of which M cells are part of (30,31). There it is believed 
that the bacterium will make use of CD18+ phagocytes, amongst them 
macrophages, monocytes and most notably dendritic cells, as Trojan horses to travel 
through the body first via the mesenteric lymph nodes (32–35). From the mesenteric 
lymph nodes the bacteria will find itself seeded into various organs such as liver, 
spleen, and gallbladder where the bacteria can be found within cells, such as 
macrophages resident of the organ (36–44). This seeding most likely happens via a 
primary bacteremia (32,45) that may go unnoticed by the infected individual. From 
the organs bacteria will be seeded into the bloodstream a second time resulting in 
the clinical symptoms associated with typhoid fever over a week from the initial 
ingestion of the bacteria (18,19,46). 
Typhoid fever is characterized by "influenza-like symptoms" in the form of general 
malaise and fever, but also by specific signs in both an enlarged liver and spleen, 
tender abdomen, and the possibility of having coating on the tongue (18,19,47). As 
the disease progresses the fever will increase with some individuals also getting skin 
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lesions in the form of rose spots (18,19,47). More severe complications can manifest 
in the form of gastrointestinal bleeding, intestinal perforation, confusion, and 
inflammation of several organs such as the liver and heart (18,19,47). While most 
individuals who recover completely clear the bacteria, still a few percentage continue 
excreting S. Typhi months after the clinical disease has resolved with some even 
becoming chronic carriers with the bacteria most likely residing long-term in the 
gallbladder (48–52). 
 
FIGURE 1 Illustration of the pathogenesis of typhoid fever. Following ingestion of S. Typhi the 
bacteria will travel to the intestine, across the intestinal barrier, and disseminate throughout the body.  
During the years the treatment regimen for typhoid fever has changed from antibiotic 
to antibiotic due to emergence of antibiotic resistance rendering a prevailing regimen 
useless. The original choice for treatment from 1950's onward was the protein 
synthesis inhibitor chloramphenicol (53), but the use of this antibiotic was affected 
from the 1970's on due to the discovery of S. Typhi strains harbouring 
chloramphenicol resistance (54–56). The treatment options were then expanded to 
include the folate synthesis inhibitors trimethoprim and sulfonamide in addition to the 
cell wall synthesis inhibitor ampicillin (57). However a few decades later S. Typhi 
resistant to all of these antibiotics was widespread (58,59). Today the main treatment 
for typhoid fever is protein synthesis inhibitor azithromycin, DNA gyrase inhibitor 
ciprofloxacin and cell wall synthesis inhibitor ceftriaxone (60–62), although for how 




With treatment options for typhoid fever becoming scarce the role of vaccines is ever 
more important in preventing typhoid fever. As of today there are two vaccines 
available, one of them being Ty21a, a vaccine consisting of an attenuated S. Typhi 
ingested orally, and Vi, a vaccine consisting of the outermost capsule of S. Typhi 
given intramuscularly (68,69). The immune response mounted following vaccination 
with Ty21a even results in cross-protection against paratyphoid fever (70,71). 
However, these vaccines haven't been widely adopted due to issues with long-term 
protection towards disease, resulting in the need for revaccinations approximately 
every third year, and subpar efficacy in the most vulnerable group of individuals 
namely young children (68,69).  
Due to these concerns the search for a typhoid fever vaccine continues with two 
main vaccine candidates arriving with the concept of making the Vi capsule more 
immunogenic by conjugating the polysaccharide with a strong antigen (69). One of 
the conjugate vaccine candidates aimed at better efficacy and safety for children 
consists of the Vi capsular polysaccharide conjugated to an inactive variant of 
exotoxin A from Pseudomonas aeruginosa. This vaccine candidate is termed Vi-rEA 
and has showed efficacy in young children, yet is still not licensed in any country 
(69,72–74). However, a conjugate vaccine that is licensed, albeit only in India while 
also being recommended by the WHO for endemic areas, consists of the Vi capsular 
polysaccharide conjugated with a tetanus toxoid named Vi-TT (69). This conjugate 
Vi-TT vaccine has been evaluated in children from the age of 6 months and shown to 
be superiorly efficacious to the current Vi capsular vaccine in this susceptible group 
of young children with similar results in adults in a human challenge model (75–77). 
Additionally, an aspect that might complicate the effectiveness of such vaccines is 
the fact that S. Typhi lacking the Vi-antigen have already been documented (78) and 
could possibly be selected for with an vaccine that is not targeting any antigens of 







2.3 Invasive non-typhoidal salmonellosis 
In the last few decades a different type of disease caused by S. enterica has 
emerged in the form of invasive non-typhoidal salmonellosis. This disease is not 
cause by the human-specific S. Typhi or S. Paratyphi, but instead by non-typhoidal 
serovars of Salmonella enterica serovar Enteritidis (S. Enteritidis) and S. 
Typhimurium (79–81). With invasive non-typhoidal salmonellosis still being a fairly 
recently recognized disease the estimates of the burden it causes range a lot. A 
study from 2015 estimated that amount of cases each year is 3,4 million with 
approximately 600,000 deaths globally (82), while a study from 2019 estimates there 
to be around 500,000 cases each year with approximately 80,000 deaths globally 
(2). Even though invasive non-typhoidal salmonellosis might be causing mortality 
parallel to that of typhoid fever, the pathogenesis differs significantly. The infection 
simply results in a bloodstream infection, often without any associated 
gastroenteritis, following the ingestion of the bacteria. Originally one observed the 
ability of such non-typhoidal Salmonella serovars to cause invasive disease mainly in 
AIDS patients (83), but also in malnourished individuals (81), with all this making 
Salmonella the most common non-malarial bloodstream infection on the African 
continent (79). 
As Salmonella has previously been thought to cause either typhoid fever or 
gastroenteritis the discovery of a bloodstream infection stands out. The search for 
what makes S. Typhimurium sometimes cause invasive disease has identified the 
reason to be a specific genotype of S. Typhimurium in the form of sequence type 
313 (ST313). This genotype was originally identified through sequencing (84) and is 
at present almost exclusively found in Africa with increased burden especially in 
children (79–81). A suggested reason for the emergence of S. Typhimurium ST313 
as the causative agent for invasive non-typhoidal salmonellosis is that it could be 




FIGURE 2 Illustration of the pathogenesis of invasive non-typhoidal salmonellosis. Following 
ingestion of S. Typhimurium ST313 the bacteria will travel to the intestine, across the intestinal barrier, 
and into the bloodstream where it possibly resides within immune cells.  
As to the reason for this increased invasiveness one has managed to identify at least 
one contributing factor in S. Typhimurium ST313 by showing it to have enhanced 
ability to survive within macrophages while also managing to trigger less 
inflammatory reactions from the host cells (86,87). Both of these details can be seen 
as beneficial in causing a more systemic disease, compared to non-ST313 variants 
of S. Typhimurium. Additional details on the invasiveness of S. Typhimurium ST313 
and its' evolution have recently been revealed by studies that have determined that 
ST313 has evolved from non-invasive S. Typhimurium strains by reductive evolution, 
i.e. genes being mutated into pseudogenes or mutations resulting in up/down-
regulation of genes (88). The mutations resulting in enhanced invasiveness can 
seemingly be pinpointed to changes in the genetic region for the MacAB protein. 
These proteins make up the MacAB-TolC outer-membrane efflux pump tasked with 
transporting antimicrobial compounds out of the bacterium (89,90) and resisting 
oxidative stress (91). Thus, an up-regulation of macAB transcription could be one of 
the reason for ST313s enhanced ability to survive within macrophages (92). How this 
enhanced ability to survive within macrophages correlates to the mortality caused by 
seemingly a bloodstream infection has not been studied, but one could possibly 
expect ST313 to reside within host cells when in blood as is the case for S. Typhi 




2.4 Non-typhoidal salmonellosis 
The third type of disease caused by Salmonella is non-typhoidal salmonellosis. This 
disease is what most people in the Nordic countries associate Salmonella with as it 
is characterized by profuse diarrhea due to gastroenteritis (96). Non-typhoidal 
salmonellosis is often caused by the same serovars of Salmonella as the ones 
causing invasive non-typhoidal salmonellosis, i.e. S. Typhimurium and S. Enteritidis. 
Yet the pathogenesis of the invasive and non-invasive non-typhoidal salmonellosis 
differs greatly. While non-typhoidal salmonellosis is restricted to the intestine with 
systemic involvement being rare it still causes a large burden globally; in 2010 the 
burden was estimated to be 94 million cases of gastroenteritis resulting in 
approximately 150,000 deaths each year (3).  
Following ingestion and arrival to the intestine S. Typhimurium will establish itself by 
using H2 as a source in intermediate metabolism aiding the bacteria in the initial 
colonization of the lumen of the intestine (97). From here non-typhoidal salmonellae 
will not invade deeper tissue, but instead will what seems like actively trigger an 
inflammatory response from the body by using its needle-like appendage in the form 
of a secretion system to translocate proteins into enterocytes (98–100). The action of 
translocating proteins into the enterocytes is thought to be one of the reason leading 
to the enterocytes recruiting large amounts neutrophils to the site, a hallmark for 
disease caused by non-typhoidal salmonellae, resulting in inflammation that gives 
rise to the profuse diarrhea (101–104). 
While it seems counterintuitive to actively trigger inflammation several publications 
have highlighted possible reasons for this. First, after the initial colonization the 
amount of S. Typhimurium is too low so the inflammation aids in flushing out the 
competing microbiota that is indirectly protecting the host due to the colonization 
resistance (105–107). Second, the inflammation and influx of neutrophils creates a 
very hostile environment for any organism present in the intestine by leading to for 
example lack of oxygen. This environment is taken advantage by S. Typhimurium as 
the bacterium is one of few bacteria with the ability to switch its respiration to one 
based on tetrathionate. Tetrathionate is a byproduct of oxidation of thiosulphate, 
created due to reactive oxygen species (ROS) from the inflammation, that can be 
used by salmonellae as a terminal electron acceptor (108). This ability results in an 
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overgrowth of S. Typhimurium in the gut as it the access to tetrathionate itself aids 
the bacteria to then use ethanolamine as a carbon source (109). This gives S. 
Typhimurium the opportunity to occupy the space left behind by the microbiota that 
was flushed out by the inflammation, a detail that can also be seen by the fact that 
the infection results in the reduction of both amount and complexity of the microbiota 
in the intestine (106). From hereon S. Typhimurium will continue multiplying in the 
intestine, but is restricted from proceeding further into the host by the immune 
response and ending up being flushed out of the intestine a few days later. 
 
FIGURE 3 Illustration of the pathogenesis of non-typhoidal salmonellosis. Following ingestion of S. 
Typhimurium the bacteria will travel to the intestine where it will induce inflammation. This 
inflammation manifests as an influx of neutrophils and profuse diarrhea.  
2.5 Mouse models of salmonellosis 
As briefly remarked in the beginning of this literature review, most details regarding 
the pathogenesis of the three types of diseases have been mainly studied using 
mouse models. For example with S. Typhi being solely a human-specific pathogen 
studies to molecular detail are especially cumbersome. In order to understand the 
pathogenesis of typhoid fever better there is an appropriate match-pair in S. 
Typhimurium and susceptible mice as the pair recapitulating the systemic 
dissemination seen in human typhoid fever fairly well (110–112). However, 
prominent mouse models used to study aspects of the systemic dissemination of S. 
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Typhimurium are not wild-type in that the mouse lineages, as for example the 
BALB/c, are mutants for a protein called Nramp1 (also known as slc11a1) (113).  
The importance of Nramp1, a membrane transport protein, comes from it limiting the 
ability of intracellular pathogens to proliferate within cells (114). The cells where 
Nramp1 is expressed are the same ones that S. Typhi first comes in contact with 
during typhoidal pathogenesis, in dendritic cells (115), macrophages (116), and 
neutrophils (117). The function of Nramp1 is to import metal ions into intracellular 
compartments of these cells (118,119) and in this way possibly affect the oxidative 
status (120–122) or the expression of other antimicrobial proteins (123) resulting in 
inhibition of growth of internalized organisms. Hence when this protein is non-
functional, it allows for systematic dissemination of S. Typhimurium in mice resulting 
in a typhoid fever-like disease.  
Mouse models with non-functional variant of Nramp1 do not however recapitulate 
carrier-states of typhoid fever due to the mice succumbing to the infection before 
carriage is established (110). Instead, to study carriage one infects mice with 
functional Nramp1, such as 129/Sv, with S. Typhimurium resulting in the bacterium 
causing a chronic infection (124,125). Both mouse model using Nramp1-negative 
mice and Nramp1-positive mice give insights into the pathogenesis of typhoidal 
fever. Yet neither of these models result in the mice having gastroenteritis, which is 
characteristic of non-typhoidal salmonellosis. To model this one can also use mouse 
models, such as C57BL/6, but with the mice being pre-treated with streptomycin. 
Originally the streptomycin pre-treated mouse model was discovered in the 1950's 
by showing that pre-treating mice with the antibiotic allowed for lower infectious dose 
of S. Enteritidis (126). The model was systematically launched as a model for colitis 
caused by non-typhoidal salmonellae a half a decade later (127). As such this model 
recapitulates one of the hallmarks of pathogenesis of non-typhoidal salmonellosis in 
humans by showing a massive infiltration of immune cells into the intestine and 
similar histopathology (127–129). All in all these mouse models have given 
researchers good tools to understand the pathogenesis of different Salmonella on a 





FIGURE 4 Characteristics of some mouse models for research into Salmonella infections.  
2.6 Macrophage models of salmonellosis 
As has been highlighted many times in the text, an important cell type for the 
pathogenesis associated with Salmonella is the macrophage. This detail is 
specifically pertinent to the systemic dissemination of S. Typhi during typhoid fever, 
and S. Typhimurium during typhoid fever-like illness in susceptible mice, as the 
bacteria can be found within splenic (36,38,41,42) and liver macrophages (37,38,44) 
during an infection. As such, a lot of research have been performed using 
macrophage cell lines in order to determine genes that are needed for the ability of 
Salmonella to cause disease. But what is so special and interesting about the fact 
that Salmonella can be found within macrophages? The detail that is the most 
striking in this relationship is the fact that even though macrophages have numerous 
functions ranging from bone remodeling to iron recycling, macrophages are mainly 
known for ingesting foreign agents, such as bacteria, via phagocytosis and then 
degrading them in intracellular compartments (130).  
Currently macrophages are seen as two distinct populations based on their origins, 
both of which possibly are targeted by Salmonella. Previously it was thought that all 
macrophages in the body would be seeded from the bone marrow continuously by 
the production of motile monocytes that would then develop into specific 
macrophages for each tissue. Instead tissue resident macrophages, such as the 
Kupffer cells of the liver and marginal zone and red pulp macrophages of the spleen, 
are actually embryonically seeded to each organ and renew there during the lifetime 
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of the host while monocyte-derived macrophages mainly arrive during inflammation 
and are distinct from resident macrophages (130–132). Hence even thought it has 
been postulated that typhoid fever involves S. Typhi entering macrophages near the 
M cells and then disseminating throughout the body within them (as presented in 
(133)) the reality is probably slightly more complex since tissue resident 
macrophages are non-motile. Regardless, Salmonella is able to grow within these 
cells evolved to ingest and degrade, making the use of macrophages in cell culture 
prominent.  
One of the most commonly used macrophage cell line in Salmonella research are 
the RAW264.7 cells. This cell line couples well with mouse models used to study the 
systemic spread of S. Typhimurium as the RAW264.7 cells were originally isolated 
from BAB/14 mice following isolation of tumorous tissue after infecting the mice with 
Abelson Leukemia Virus (134). This ties the cells very well to the mice used for 
studying typhoidal pathogenesis, BAB/14 mice are actually BALB/c mice with the 
single difference of them carrying structural genes for immunoglobulin from another 
mouse strain (135). Hence, RAW264.7 cells do not produce functional Nramp1, as 
neither does the BALB/c mice. As such RAW264.7 cells have been used to show the 
importance of Nramp1 by showing that the functional expression of the protein 
inhibits the intracellular replication of S. Typhimurium in the RAW264.7 that 
otherwise allow for replication of the bacterium (136).  
2.7 Uptake/Invasion into macrophages 
The importance of the relationship between Salmonella and macrophages for 
pathogenesis becomes evident by the fact that mutants of Salmonella that do not 
have the ability to survive within macrophages are not able to cause disease (137). 
But what actually happens when a macrophage ingests a Salmonella bacterium? 
A first step for the macrophage is to catch and ingest its prey, which most often 
happens via phagocytosis. Phagocytosis can proceed in a few different ways by for 
example antibodies or complement factors binding to the bacterium, aiding the 
macrophage to phagocytize the bacterium (138). However, already at this stage it is 
not clear if phagocytosis is the only means for Salmonella to enter macrophage. This 
due to Salmonella having the ability to actively invade cells, albeit a detail best 
characterized in non-phagocytic cells, by translocating proteins into host cells using 
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the needle-like type-three secretion system-1 (T3SS-1) encoded on the Salmonella 
pathogenicity island-1 (SPI-1) (133,139). Instead it has been suggested that 
Salmonella enters macrophages not due to phagocytosis, but actually by the 
bacteria inducing membrane ruffles in the macrophage resulting in ingestion via 
macropinocytosis (140). The reason such membrane ruffles are induced is in part 
due to the proteins Salmonella translocate having actin-polymerizing activities that 
results in changes of the cytoskeleton of the macrophage (141–143). For example 
proteins SipC and SipA, translocated via T3SS-1, have been shown to actively 
initialize nucleation of actin polymers and stabilizing the subsequent actin leading to 
manipulation of the host cytoskeleton (144–147). 
 
FIGURE 5 Illustration of the injection apparatus used by Salmonella when invading host cells. The 
type 3 secretion system-1 translocates effectors exemplified by SipA and SopE into the host cell 
resulting in modulation of the actin cytoskeleton and activation of small GTPases. 
 
 15 
The translocated SipC and SipA are not enough by themselves to induce invasion of 
host cells. Examples of other proteins being translocated into the host cell by the 
T3SS-1 are SopE, SopE2, and SopB. These proteins have in common that they 
modulate signaling pathways in the cell in order to aid the uptake of Salmonella. 
SopE and SopE2 are both guanine nucleotide exchange factors that work by 
converting inactivated forms of the host Cdc42 and Rac1 into active forms by 
exchanging their bound guanine nucleotide from GDP to GTP (148–150). This 
activation of Cdc42 and Rac1 will lead to downstream effects on the actin 
cytoskeleton resulting in ruffling of the membrane of the host cell (151–153) resulting 
in uptake of Salmonella (139). SopB on the other hand is not a guanine nucleotide 
exchange factor, but instead possesses phosphatase activity towards 
phosphoinositide (154). This enzymatic activity causes accumulation of the signaling 
molecule phosphatidylinositol-3-phosphate in the host cell leading to formation of the 
phagosomes wherein Salmonella will initially reside within the cell (155–157).  
2.8 First phase within the macrophage 
Whether the majority of Salmonella enter macrophages by actively invading or 
through phagocytosis it seems that the subsequent steps of the pathogenesis of 
Salmonella within the macrophage are independent of means of entry (158). When 
inside the cell Salmonella finds itself in what looks like a normal phagosome (159) 
used to ingest and degrade any bacteria. However, this phagosome will instead 
quickly develop into a spacious phagosome (140) that will eventually end up 
becoming a Salmonella-containing vacuole (SCV) (160–162). What distinguishes 
these SCVs from a normal phagosome, or the subsequent phagolysosome, is the 
fact that the intracellular compartment is under the control of Salmonella resulting in 
the SCV having a modified profile of host proteins associated with it (133,160). This 
control is mediated by Salmonella using an other secretion system T3SS-2 encoded 
on the SPI-2 genetic region that is induced in Salmonella during intracellular growth 
(163). 
While the T3SS-2 is similar to T3SS-1 in structure, the proteins being translocated 
into the host cell via T3SS-2 Salmonella have different functions. Many of these 
proteins have postulated to have specific tasks in trying to inhibit the mechanisms 
that the macrophage employs in trying to kill Salmonella. The importance of the 
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T3SS-2 translocated proteins is very clear from the fact that Salmonella lacking the 
capacity to produce these components is not able to proliferate in mice, nor within 
macrophages in cell culture (164–167). Following the formation of the early SCV the 
process of acidification of the SCV starts from the neutral pH of the contents arriving 
from outside the cell and eventually reaching pH 4.5 as the SCV progresses towards 
the phagolysosomal stage (168). Even though this acidification is a normal part of 
the degradative pathway for the macrophage Salmonella does not inhibit it from 
taking place, but rather slows the process down (169). In contrast, the acidification of 
the SCV is required for Salmonellas ability to grow within macrophages (170) due to 
acidity being a signal for secreting some of the proteins modulating the SCV 
(169,171).  
2.9 Avoiding kil l ing by the macrophage 
In general the stage when most organism internalized by macrophages get killed is 
when the phagosome that the organism resides in fuses with lysosomes. Lysosomes 
are intracellular vesicles containing degradative enzymes that when fused with the 
phagosome create a phagolysosome (168). For Salmonella to be able to survive 
within macrophages it has to avoid this fusion of the early SCV and the lysosomes 
(172,173). It is thought that SPI-2 is important for this avoidance, however, there are 
no studies showing a direct mechanism of how Salmonella would inhibit this 
lysosome-to-phagosome fusion. Instead there are refuting data indicating that 
Salmonella actually does not inhibit fusion of the SCV with lysosomes, but instead 
simply resists killing by the lysosomal content (174–176). A similar finding has also 
been observed in an other study, albeit not with macrophages, but instead with 
epithelial cells (177). There might be somewhat of a middle way between these 
contradicting studies in that a study proposes that Salmonella manages to do avoids 
being killed by lysosomes by segregating its population into several SCVs. In this 
way there simply aren't enough lysosomes to fuse with the various SCV and hence 
the lysosomal content are depleted by Salmonella letting part of the population be 




FIGURE 6 Illustration of the endocytic process of a macrophage when ingesting a non-pathogenic 
bacteria (left) compared to Salmonella (right). pH of the phagosomes containing the non-pathogenic 
bacteria acidifies faster compared to the ones containing Salmonella. Salmonella also possibly is able 
to inhibit lysosomal fusion with the phagosome.  
Whatever steers the relation between lysosomes, lysosomal fusion and the SCV, this 
form of killing is not the only way for a macrophage trying to combat intracellular 
Salmonella. A very important additional aspect is the ability of macrophages to utilize 
redox chemistry. This includes production of ROS and reactive nitrogen species 
(RNS) that target Salmonella within the compartment it resides in. One very 
prominent enzyme complex in this ROS-mediated killing is the NADPH oxidase. 
NADPH oxidase uses oxygen and NADPH to produce superoxide and hydrogen 
peroxide in an event known as the respiratory burst (179–181). The importance of 
NADPH oxidase in controlling an infection with Salmonella has been shown 
experimentally in mice and macrophages in cell culture where the lack of NADPH 
oxidase impairs the hosts ability to resist a Salmonella infection (182–184). As a 
matter of fact the importance of NADPH oxidase is not only seen in experimental 
settings but also in humans in the disease called chronic granulomatous disease, a 
disease involving mutation in genes encoding for components of NADPH oxidase, 
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resulting in increased susceptibility towards intracellular pathogens such as 
Salmonella (185).  
But how come Salmonella is still able to cause infections even in macrophages and 
mice with functional NADPH oxidase? Once again it seems that the answer can be 
found within the genetic region of SPI-2 which has been shown to allow for 
Salmonella to evade the NADPH oxidase by somehow blocking the enzyme 
complexes association with the membrane of the SCV (186–188). Yet, as with 
lysosomal fusion to the SCVs, similar contradictions exist for the NADPH oxidase in 
that the effect of the enzyme is more pronounced in the very beginning of the 
macrophage ingesting Salmonella, a time-frame where SPI-2 is proposed not to be 
active. This points to a temporal discrepancy regarding on how SPI-2 could block 
NADPH oxidase (189). Additionally, the actual importance of the NADPH oxidase in 
macrophages during a Salmonella infection in mouse might be confused with that of 
the effect of NADPH oxidase of neutrophils and monocytes, as is proposed in a 
study showing that macrophage NADPH oxidase does not kill Salmonella efficiently 
during infection, but that of the neutrophils and monocytes do (190).  
Still, SPI-2 is not the only defense Salmonella uses towards the effects of the 
NADPH oxidase. As nothing is black or white in biology, but much of it is grey, 
Salmonella still gets exposed to ROS that have the ability to damage bacterial 
periplasmic proteins (191). For this Salmonella has enzymes that detoxify such ROS 
one of which is called superoxide dismutase (192,193). Superoxide dismutase works 
by converting superoxide radicals into less reactive hydrogen peroxide. This has 
been shown to be important for Salmonella during growth within macrophages and in 
mice (191,193,194) by a proposed mechanism that superoxide dismutase does not 
let superoxide reach targets in cytosol of the bacterium (195). The issue is not solved 
by superoxide dismutase alone as the by-product of its enzymatic activity is creating 
hydrogen peroxide. But Salmonellas defense extends beyond superoxide in that it 
also possesses catalases and alkyl hydroxyperoxide reductases, enzymes that 
detoxify hydrogen peroxide into water and oxygen (192), while also having the ability 
to regulate the permeability of the outer membrane to block entry of hydrogen 
peroxide (196). As superoxide dismutase, the hydrogen peroxide quenching 
enzymes catalase and alkyl hydroxyperoxide reductase have also been shown to be 




FIGURE 7 Illustration of the innate immunity effector NADPH oxidase and its production of 
superoxide and the superoxide detoxifying enzyme of Salmonella in superoxide dismutase. Chemical 
equations simplified.  
Yet, with the lysosomes and ROS one would think that this would be enough of an 
arsenal for the macrophage to fight invaders, but still the macrophage has additional 
mechanisms of killing. One of these additional mechanisms are very analogous to 
the ROS-mediated killing in the form of RNS (200–202). These RNS are produced as 
by-products following production of nitric oxide by the inducible nitric oxide 
synthetase (iNOS), an enzyme mainly found active in the cytosol of macrophages 
(203–206). The produced nitric oxide can then further react with for example proteins 
involved in metabolism that contain cysteines (207) or with ROS produced by the 
NADPH oxidase resulting in new toxic compounds (203,208). This synergy between 
the NADPH oxidase and iNOS allows for the creation of peroxynitrate, a very strong 
oxidant with vast biocidal activity (209–211). All of these actions contribute to the 
importance of iNOS in defense against pathogens as shown by iNOS being needed 




However, as with NADPH oxidase Salmonella has also defense mechanism against 
iNOS similar to the ones used for counteracting NADPH oxidase in the form that the 
SPI-2 genetic locus is needed for Salmonella to survive in macrophages having 
iNOS activity (216). How this SPI-2 mediated defense against iNOS works is not 
known, but curiously enough it seems that it's an arms race in the fact that nitric 
oxide itself generated by macrophages is able to repress the transcription of SPI-2 
(217). Other than SPI-2 the main protein in defense against nitric oxide is the 
flavohemoglobin Hmp, which is under regulatory control of the NsrR regulon (218), 
whose enzymatic function involves detoxifying nitric oxide by converting it to nitrate. 
The ability of Hmp to do this has been shown important for growth in macrophages 
in culture and in mice, hence most likely relating it to the defense against iNOS 
(219,220). In somewhat of a similar fashion it has been proposed that the nitrate 
transporter NirC is also involved in protection against iNOS in mice and 
macrophages by the way of reducing the amount of nitric oxide in the bacteria (221). 
While an other mechanism of defense against nitric oxide is simply to absorb the 
damage by quenching it via antioxidants such as glutathione (222). 
 
FIGURE 8 Illustration of the innate immunity effector iNOS and its production of nitric oxide and the 
nitric oxide detoxifying enzyme of Salmonella in flavohemoglobin Hmp. Chemical equations simplified.  
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2.10 Creating conditions for proliferation within the macrophage 
In the event that Salmonella manages to survive all of the assaults from the 
macrophage it will find itself creating a network of intracellular compartments that 
allows for proliferation. One of the effector proteins encoded by SPI-2 that is needed 
to establish this is SifA. Although most studies performed on the role of SifA in 
forming the network of intracellular compartments called Salmonella-induced 
filaments (SIF) has been performed in epithelial cells (reviewed in 145,203–205) the 
importance of SifA in macrophages is unquestionable, albeit it is unclear if actual 
SIFs form in them (226). First, if Salmonella is lacking SifA it will be more likely found 
in the cytosol of the macrophage, instead of in the vacuolar compartment of the 
SCV, indicating that the protein is important for for the integrity of the SCV in 
macrophages (36,227,228). How SifA helps in the maintenance of integrity of the 
SCV in macrophages is not fully understood, but data from mainly epithelial cells 
infected with Salmonella indicates that SifA blocks the accumulation of motor 
proteins, such as kinesin, to the SCV and this way possibly decreases the 





FIGURE 9 Illustration of the injection apparatus used by Salmonella when within the host cell. The 
T3SS-2 translocates effectors exemplified by SifA into the host cell resulting in stability of the vacuole 
within which Salmonella resides.  
The establishment of these stable intracellular compartments in the form of SCVs is 
a prerequisite for Salmonella to be able to proliferate within the cell. This due to the 
fact that the structures formed with the help of SifA promote the nutritional acquisition 
from other intracellular compartments into the SCV (231,232), an important aspect of 
intracellular pathogenesis (233–237). However, Salmonella seemingly is able to also 
acquire nutrients into the host cell where it resides by somehow stimulating the cell. 
This is the case for iron, an important metal for many organisms, through the fact 
that Salmonella is able to steer macrophages to phagocytize erythrocytes and in this 
way gaining access to increasing amounts of iron while within the macrophage 
(38,238–240).  
Even though the majority of the aspects regarding the intracellular life of Salmonella 
in the macrophage that have been highlighted in the text above have mainly been 
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determined by experimentation in mice and cell culture using S. Typhimurium the 
results of such studies most likely highlight details also pertaining to human typhoid 
fever. For example the intracellular life of Salmonella in humans has also been 
established during diagnosis of typhoid fever via blood cultures and bone marrow 
biopsies as S. Typhi is mainly found within cells in the samples (93–95), hence  
corroborating the relevance of studies on intracellular S. Typhimurium in various 




3 RESEARCH AIMS 
Antibiotic resistance and intracellular pathogenesis were the main focus of this thesis 
with both being important aspects of the biology of Salmonella. Studies on these 
issues were undertaken to decipher new information on genetic and molecular 
determinants needed by Salmonella to resist an antibiotic, as well as to proliferate 
within host cells. 
As such one aim of Paper I was to study the importance of muramyl endopeptidases 
in the ability of S. Typhimurium to resist antibiotics. For Paper II the aim was to 
characterize the importance of a regulator of said muramyl endopeptidases in the 
form of how periplasmic protease Prc affected the fitness of S. Typhimurium during 
intracellular pathogenesis in macrophages and during infection in mouse. For Paper 
III the aim was to characterize the response of innate immunity effector iNOS in 




4 MATERIALS AND METHODS 
4.1 Bacteria 
The bacteria used in this thesis can be divided into two categories. One of the 
categories includes the Salmonella strains under study, S. Typhimurium SR-11 and 
S. Typhimurium 14028. Occasional confirmatory experiments were also performed 
using S. Typhimurium SL1344. The parent of strain S. Typhimurium SR-11 was 
originally isolated from infected mouse Peyer's patches (241) and selected further for 
a more virulent variant able to cause chronic infection resulting in S. Typhimurium 
SR-11 χ4665 used in this thesis (242). S. Typhimurium 14028 is a laboratory strain 
obtained from the American Type Culture Collection and S. Typhimurium SL1344 is 
derived from a study attempting to create a live Salmonella vaccine (243).  
The other category is bacteria used for genetic manipulation. This category includes 
S. Typhimurium LB5010, a mutant for the DNA restriction modification system (244), 
which was the main strain used when making mutations into the genome of 
Salmonella. From this strain the mutations were then transferred to either SR-11, 
14028 or SL1344 by transduction with the help of phage P22 (245). For cloning 
intermediary strains of Escherichia coli (E. coli) Top10, available from Thermofisher, 
or E. coli  TG1, available from Nectagen, were used before purification and 
transformation into S. Typhimurium SR-11 or 14028.  
4.2 Genetic manipulation of bacteria - Removing genes 
Many experiments in this thesis are based on genetic manipulation in the form of 
removal of genes of S. Typhimurium followed by phenotypic observations. This is 
done by so called recombineering (246). Recombineering is based on homologous 
recombination where DNA fragments, in the form of a selection marker, are 
introduced into bacteria via electroporation. This DNA fragment is then subsequently 
incorporated into the genome, with the help of an exogenous recombineering 
system, in place of a gene of interest. The bacterium is henceforth described as 
Δgene-mutant for the gene that was deleted.  
More specifically, mutants created in this thesis are done using the pSIM 
recombineering system (247). To be able to create mutants one has to produce the 
DNA fragment using PCR. The DNA fragment is to contain an antibiotic resistance 
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gene, i.e. the selection marker, that is flanked by the upstream and downstream 
regions of the gene one intends to remove. This can be accomplished by first 
designing primers, using annotated genome sequences from the NCBI database, by 
which one part of the primer anneals to the upstream or downstream region of the 
gene of interest and the other part anneals to a template plasmid containing the 
selection marker. The designed primers and template plasmid are then mixed and 
the final DNA fragment can be purified following PCR. 
 
FIGURE 10 Illustration of the principles in creating a DNA fragment used to mutate/remove genes. 
The black part of the primers corresponds to sequences that are upstream (primer #1) or downstream 
(primer #2) of the gene of interest. The red part corresponds to sequences of the selection marker on 
the plasmid and are used in the PCR to amplify the antibiotic resistance gene by using the plasmid as 
a template. This way the created DNA fragment has an antibiotic resistance gene flanked by 
sequences matching the bacterial chromosome.  
Having produced the DNA fragment bacteria are prepared for recombineering. To 
start off a pSIM plasmid is introduced into the bacteria one wishes to mutate, i.e. S. 
Typhimurium LB5010, and the bacteria are then grown to the exponential growth 
phase at 32°C. This temperature is important since the pSIM plasmids contains a 
temperature sensitive origin of replication. After reaching the exponential growth 
phase the bacteria are moved to 42°C in order to induce the temperature-dependent 
expression of the bacteriophage λ recombination system from the plasmid. This  
recombination system consists of three genes encoding the proteins Exo, Beta and 
Gam (246,247). Exo exonuclease is thought to trim the incoming DNA fragment to 
allow for Beta, a single strand DNA binding protein, to protect the newly trimmed 
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fragment with Gam inhibiting the endogenous bacterial degradation system meant to 
target incoming foreign DNA (246,247). 
 
FIGURE 11 Illustration showing DNA fragment created with PCR being electroporated into bacterial 
cell. The DNA fragment will be incorporated into the chromosome in the place of a gene of interest, 
based on the homologous sequences on the DNA fragment (in black), with the help of λ 
recombination system induced from the pSIM plasmid. This will yield a mutated bacteria.  
Following induction the bacteria are prepared for electroporation by washing and 
mixing with the PCR-generated DNA fragment, electroporated, and left to recover in 
growth media resulting in transformation and recombination of the DNA fragment. 
After recovery the bacteria are plated onto agar plates containing the antibiotic 
corresponding to the selection marker designed into the DNA fragment. The colonies 
yielded the next day are the ones that have successfully incorporated the DNA 
fragment in the place of the gene of interest and hence a mutant has been created. 
From hereon the mutation is transferred with the help of phage P22 via transduction 
into SR-11, 14028 or SL1344.  
4.3 Genetic manipulation of bacteria - Complementing genes 
Having observed a phenotype in a mutant one can confirm that the gene of interest 
is responsible for said phenotype by genetic complementation. In this one transforms 
a plasmid containing the gene of interest back into the mutant to observe whether 
the phenotype is reverted back to wild-type. In this thesis the plasmids containing 
genes of interest have been produced by both restriction digestion/ligation cloning 
method and in vivo assembly (IVA) cloning.  
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Cloning via restriction digestion/ligation is based on designing primers to amplify a 
gene of interest from a chromosomal template in parallel with designing restriction 
sites into the primers. The choice of the restriction site has to match the plasmid 
vector of choice, i.e. the plasmid one wants to clone into, as plasmids have multiple 
cloning sites incorporated into them consisting of several restriction sites. Once the 
gene of interest has been amplified by PCR both the DNA fragment and the plasmid 
vector are digested using restriction enzymes. This results in two linear DNA 
fragments, i.e. the PCR product and the plasmid, that have corresponding overhangs 
resulted from the cleavage. These can now be fused together via a ligation reaction 
where a ligase, an enzyme ligating DNA together, will couple the digested DNA 
fragment and plasmid together at the cleavage sites. This plasmid will then be 
transformed into appropriate bacteria for further replicative amplification and 
purification. 
A more recent, and frankly more simple, way to perform cloning is by using IVA 
cloning (248), a method based on the endogenous homologous recombination 
system of the bacteria. One designs primers that will amplify the gene of interest 
from a chromosomal template, but instead of designing restriction sites into the 
primers one adds sequences that will overlap with the plasmid vector one intends to 
clone into. Similarly one designs primers that will create a linear version of the 
plasmid vector when amplified in PCR. This way one has a DNA fragment containing 
the gene of interest flanked by overlapping regions to the linear plasmid vector. The 
DNA fragment and linearized vector are then transformed into bacteria whereby they 
will be fused by the homologous recombination system of the bacteria. The plasmid 
is then purified from the recipient and transformed into the appropriate strain. 
4.4 Antibiotic sensitivity testing 
For testing antibiotic sensitivity this thesis employs three different methods in disk 
diffusion, broth dilution, and drop-on-lawn. In disk diffusion one adds a specific 
amount of an antibiotic solution to a paper disk. This paper disk is then placed on an 
agar plate where bacteria shortly before have been evenly spread out on. After 
allowing for overnight growth one is able to measure an inhibitory zone around the 
antibiotic disk. The measurements can then be compared between wild-type and 
mutants. Broth dilution is used to determine the minimum inhibitory concentration 
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(MIC) by culturing bacteria in growth media containing a scale of concentrations of a 
specific antibiotic. The MIC is determined as the lowest concentration where no 
bacterial growth is visibly present in the media following incubation. Drop-on-lawn 
can be used to visualize antibiotic sensitivity by applying a dilution series of bacteria 
in droplets onto an agar plate infused with a specific antibiotic. Following incubation 
one can observe differences between wild-type and mutants by looking at whether 
there is differences in growth of the droplets of the dilution serie.  
4.5 β-galactosidase release assay 
β-galactosidase (LacZ) release assay can be used to study autolysis in Salmonella 
as it does not possess the gene for LacZ, unlike E. coli. In this thesis the plasmid 
pKTH3088, which constitutively expresses LacZ, is transformed into Salmonella. 
This results in the cytosol of wild-type and mutants containing LacZ with the enzyme 
only being present outside the bacterial cell if the cell undergoes lysis. The presence 
of LacZ can be measured by adding ortho-nitrophenyl-β-galactoside that when 
metabolized by LacZ yields a colour change. Hence, when bacteria containing 
pKTH3088 are subjected to a trigger for autolysis, for example a β-lactam antibiotic, 
one can measure this by collecting the supernatant and determine the amount of 
extracellular LacZ by inferring from colour intensity and in this way know whether a 
mutant is more likely to autolyse compared to wild-type.  
4.6 Gentamicin protection assay 
Gentamicin protection assay can be used to measure various aspects of 
host-pathogen interactions such as the ability of bacteria to invade cells or to grow 
within them. This method is not exclusive to Salmonella research as it can also be 
used for other intracellular bacteria with the blueprint for the method already 
published in the 1970's (249). A few years later it was shown that the antibiotic 
gentamicin is poor at killing intracellular bacteria, possibly due to it not entering 
eukaryotic cells, leading to the creation of what now is known as the gentamicin 
protection assay (250).  
In this thesis the gentamicin protection assay is used to determine the ability of 
Salmonella to proliferate within RAW264.7 cells during an overnight infection and as 
a basis for microscopy in order to study the innate immunity effectors of RAW264.7 
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cells. For these experiments the RAW264.7 cells were cultured in a 24-well plate and 
infected with S. Typhimurium at a multiplicity of infection (MOI) of 10. Cells were then 
incubated 37°C and 5% CO2 for up to 1 hour after which the media was replaced 
with media containing gentamicin. After this, media containing gentamicin was 
removed with further experimentation depending on the aim of the study; one can 
lyse the macrophages and retrieve the bacteria in order to determine the amount of 
internalized bacteria or leave bacteria to grow overnight with either retrieving the 
bacteria the to see the proliferation or to fix the sample and stain them for 
microscopy.  
 
FIGURE 12 Illustration of the gentamicin protection assay and the various uses of it in this thesis. 
The first two hours post-infection contain killing of extracellular bacteria by gentamicin. CFU stands for 
colony-forming unit which is determined by calculating number of colonies on agar plates following 
lysis of the macrophages and retrieval of the internal bacteria.  
4.7 Immunofluorescence microscopy 
In this thesis immunofluorescence microscopy was used for detection of hypoxia, 
presence of iNOS, and protein synthesis in RAW264.7 cells. All microscopy starts off 
with fixation of the samples, often by formaldehyde. Immunofluorescence is based 
on antibodies conjugated with fluorescent molecules, applied after fixation, from 
which the signal can then can be detected when imaging using a fluorescence 
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microscope. These antibodies are often not directly binding to the signal that is being 
measured, but instead function as signal amplifiers. In the case of hypoxia the 
primary molecule that the antibody binds to is pimonidazole, while for protein 
synthesis the antibody binds to is puromycin, and for detecting iNOS the antibody 
binds to an anti-iNOS antibody that itself is directly binding to iNOS. 
4.8 Competitive infection in mouse 
To study whether mutations in the genome of S. Typhimurium affect the bacterium’s 
fitness in a more complex system compared to a cell culture, competitive infection in 
mice can be used. The competition between a mutant and wild-type is performed by 
inoculating the bacteria in a 1:1 mutant/wild-type ratio, determined using optical 
density and confirmed by enumerating the colony-forming unit (CFU) of each, here 
applying BALB/c mice. Three days later the mice were sacrificed and liver, spleen 
and gallbladder harvested. From the organs the ratio of the mutant to wild-type is 
determined by recovering the bacteria and enumerating the CFU for mutant and 
wild-type, which can be done due to the mutant having a selection marker. 
 
FIGURE 13 Illustration of a competitive infection in mice. CFUMut stands for the colony-forming unit 




4.9 Ethical considerations 
As has been described in the literature review section, the human-specific S. Typhi 
causes typhoid fever which is a disease with high mortality. Due to this it is 
cumbersome to work with S. Typhi as the safety protocols involved in working with S. 
Typhi require trained personnel and special laboratories. However, as a 
complementary way to try to understand the pathogenesis of S. Typhi researchers 
have used the less pathogenic S. Typhimurium instead. The advantage with 
choosing S. Typhimurium is that one of its natural hosts is the mouse and in 
experimental infections the mouse recapitulates various aspects of the human-
specific disease typhoid fever. As S. Typhimurium requires standard  biosafety 
protocols for a pathogen it makes Salmonella research available to more 
researchers while also enabling faster progress.  
The ethical considerations within this thesis mainly in regard to experimentation 
using animals. However, in order to minimize this the work in this thesis is always 
first performed in cell culture setting when studying the pathogenesis of intracellular 
Salmonella infection. Only thereafter did we move onto animal models in an effort to 
try to confirm if our observations made in a cell culture settings holds in a host 
animal, a much more complex environment for the bacteria, in order to asses 
whether there is a possibility of our findings to be translated into potential future 
targets for treatment for example. Hence I believe the ethical aspects of using mouse 
models to study Salmonella pathogenesis are a matter of balancing cost to benefit. I 
believe that the single animal experiment performed in this thesis outweighs the 
ethical costs by offering great insight into the role of a specific enzyme in the 
pathogenesis of Salmonella and this knowledge could be used in the future to help 





5 RESULTS AND DISCUSSION 
5.1 Paper I 
In Paper I we set out to study proteins involved in degradation of peptidoglycan (also 
known as murein) of the cell wall within S. Typhimurium. As a vast majority of 
antibiotics that have been successful throughout history one way or another target 
the cell wall such proteins are of interest. However, most such antibiotics have 
focused on targeting the machinery that synthesizes the cell wall. Yet, less focus has 
been put on the flipside of this function i.e. enzymes that cut or degrade the cell wall. 
Such enzymes are collectively referred to as peptidoglycan hydrolases (251,252).  
Mechanical functions of peptidoglycan hydrolases include creating space in the 
existing peptidoglycan mesh for new pieces to be incorporated and degradation of 
old peptidoglycan in a continuous turnover. The enzymes of interest in Paper I 
belong to peptidoglycan hydrolases, more specifically termed muramyl 
endopeptidases as they cleave peptidoglycan within the cell wall (251,252). 
Paper I studies how the sensitivity of S. Typhimurium to various antibiotics is affected 
when one removes one or several of said muramyl endopeptidases. The main focus 
was a muramyl endopeptidase named MepS (known as Spr in Paper I). MepS has 
been characterized in vitro to be a DD-endopeptidase that cleaves D-ala-mDAP 
cross-links in the peptide bridges between the glycan strands of the peptidoglycan. 
Such enzymatic activity is proposed to be required for incorporation of new 
peptidoglycan into the existing mesh of the cell wall (253). In this we find that by 
removing mepS from S. Typhimurium the bacterium becomes sensitized to 
vancomycin, an antibiotic that inhibits cell wall synthesis by binding to peptides in 
peptidoglycan precursors hence sterically blocking penicillin-binding proteins (PBPs) 
from accessing their substrate (254,255).   
This sensitization towards vancomycin is a curiosity since vancomycin is known to 
not work against Gram-negative enteric bacteria, of which S. Typhimurium is one. 
This resistance relies on the outer membrane that overlies the cell wall resulting in 
vancomycin not being able to access its target due to the large size of the antibiotic 
(254). This kind of resistance towards an antibiotic is known as intrinsic antibiotic 
resistance as simply a feature, i.e. the outer membrane, seemingly is the component 
needed for resistance, as opposed to spontaneous mutation arising resulting in 
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antibiotic resistance. As a first step in Paper I we showed the sensitization towards 
vancomycin after removal of mepS from S. Typhimurium was not due to a 
destabilization of the outer membrane allowing for vancomycin to reach its target, but 
due to some other mechanism.  
 
FIGURE 14 Illustration highlighting the cleavage site of muramyl endopeptidase MepS (also known 
as Spr). The cell envelope of the bacteria consists of the outer membrane, cell wall, and inner 
membrane. Within the cell wall MepS cleaves the peptide bond between meso-diaminopimelic acid 
(m-DAP) and D-alanine (D-ala).  
We subsequently report in Paper I that the mechanism by which S. Typhimurium 
becomes sensitized towards vancomycin when removing mepS is due to the 
bacteria being more prone to undergo autolysis. Autolysis is a phenomenon where 
specific cell wall degrading enzymes are activated, following for example stress due 
to antibiotic exposure, resulting in seemingly uncontrolled cleavage of the cell wall 
and bacterial lysis (256,257). In Gram-negative bacteria enzymes such as amidases 
and transglycosylases (258–260), and muremyl endopeptidases (256,261,262) are 
proposed to be the main drivers in autolysis. One of the main stressors studied that 
leads to autolysis are β-lactam antibiotics i.e. antibiotics that target enzymes 
synthesizing the cell wall and their transpeptidase activity (263,264). Yet Paper I is 
the first report implicating muramyl endopeptidase MepS in autolysis in addition to 
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showing that vancomycin is able to induce autolysis in a Gram-negative enteric 
bacterium.  
But how does MepS fit into the autolytic system involving amidases, a 
transglycosase, and other muramyl endopeptidases? Recently some studies have 
come to shed light on what might be happening during autolysis by using β-lactam 
antibiotics as the trigger. In this it has been shown that the machinery synthesizing 
the cell wall at the site of cell division, i.e. the "divisome" of which one component is 
PBP3 that is targeted by β-lactams, needs to be assembled at the site (260). When 
this machinery is inhibited the autolytic process is somehow initiated resulting in 
autolysis. The reason for this has been proposed to be due to autolytic enzymes 
starting to degrade cell wall while being under the impression that the cell wall 
synthesizing machinery, which is inhibited by the β-lactam, is synthesizing new cell 
wall at the same time (265). This imbalance between degradation and synthesis 
would then result in autolysis. 
Interestingly we show that for the intrinsic vancomycin resistance resulting from 
MepS being present, MepS needs to be catalytically active. However, on the 
contrary to other muramyl endopeptidases proposed to be autolysins, such as PBP7, 
MepS seems to act opposite to an autolysin in the sense that the lack of mepS 
results in S. Typhimurium being more prone to undergo autolysis and not less. 
Additionally it has been observed in E. coli that overexpression regarding MepS, 
even a catalytically inactive form in a wild-type background results in the bacteria 
becoming more resistant to the β-lactam antibiotic mecillinam (266). Hence, the 
proposed mechanism for this effect of overexpressing MepS resulting in increased 
mecillinam resistance is far from as simple as MepS cleaving cell wall; the authors 
show that elevated MepS levels result in increased activity of PBPs that synthesize 
cell wall leading to the cellular machinery simply outrunning the inhibitory effect of 
mecillinam.  
Whether the proposed mechanistical insights made for MepS and mecillinam in E. 
coli are the same that drives our observations made in Paper I regarding MepS and 
vancomycin is not clear. To try to understand the underlying mechanism we then 
selected for spontaneous mutations that would result in vancomycin resistance in 
bacteria lacking mepS. In this we found an additional player in the form of the the 
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periplasmic protease Prc (known as Tsp in paper I) that when removed reverted the 
phenotype of the ΔmepS-mutant to wild-type, indicating a connection between Prc 
and MepS. This connection was already previously well established in E. coli as 
MepS has been proposed to be the main substrate for Prc (267). As such, one 
possible mechanism of how the lack of mepS indirectly might affect autolysis is that 
the function of Prc is instead focused on other targets, such as the cell wall 
synthesizing enzyme PBP3 (268–270) or muramyl endopeptidase PBP7 (271,272), 
resulting in dysregulation of the autolytic system due to excessive 
processing/degradation of its components.   
In this way we show in Paper I that the outer membrane is not the only protective 
factor for a Gram-negative enteric bacterium in its defense towards vancomycin. 
Instead we suggest that the intrinsic antibiotic resistance towards vancomycin is 
probably at least twofold in that the outer membrane acts as a protective barrier, but 
somehow molecules of vancomycin can gain access to the cell wall resulting in a 
need for a second line of defense in the form of MepS. Hence, Paper I highlights 
additional features of vancomycin and the resistance determinants in a Gram-
negative enteric bacterium. We believe all this increases our understanding of basic 
biology of S. Typhimurium in regards to antibiotic resistance and hopefully will be 
useful for future studies.      
5.2 Paper II 
As we observed a phenotype for the bacteria lacking prc in Paper I we decided to 
further probe the Δprc-mutant for additional phenotypes. Prc is a periplasmic 
protease originally identified as a protease that targets proteins with nonpolar C 
termini through recognition via its PDZ domain (273–278). The function of Prc is 
strongly associated with the lipoprotein NlpI to which the protease docks on the inner 
leaflet of the outer membrane (278–280). This docking to NlpI is needed for full 
activity of Prc in degrading its substrate MepS (267,278). Yet even though Prc has 
been previously studied in vitro the role of the protease during pathogenesis is less 
well characterized. Hence in Paper II we found that S. Typhimurium lacking prc had 
a significantly reduced ability to proliferate within murine macrophage-like RAW264.7 
cells. This ability to proliferate and survive within macrophages is very central to the 
pathogenesis of typhoid fever as highlighted in the literature review section. First, in 
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order to verify that the lack of prc was the reason for this reduced ability to proliferate 
we complemented the Δprc-mutant by reintroducing the prc gene on a plasmid into 
the bacteria. This resulted in complementation of the Δprc phenotype thus 
confirming the genotype-phenotype association for the reduced ability to proliferate 
within RAW264.7 cells.  
Related to Paper I we wanted to know if there were any possible genetic 
associations to the phenotype of the Δprc-mutant by further removing genes from 
mutant and observing whether the additional mutation resulted in suppression of the 
Δprc phenotype. As described in the section for Paper I the main substrate for Prc is 
thought to be MepS. Thus the obvious starting point in trying to find a suppressive 
mutation was to remove mepS from the Δprc-mutant. Contrary to our expectations, 
the removal of mepS from the Δprc-mutant did not result in the suppression of the 
reduced ability to proliferate within RAW264.7 cells. As such for gaining tentative 
suppressor mutations instead of employing a selection-based approach, we opted 
for a candidate-based approach where known partners of Prc were removed 
sequentially and possible suppression of the Δprc phenotype was tested. In this we 
found that by removing the gene for the alternative peptidoglycan synthase PBP3SAL 
from the Δprc-mutant, the Δprc virulence phenotype was suppressed.  
PBP3SAL has not been previously shown to be associated to Prc, however a 
homologous protein to PBP3SAL, PBP3, has been shown to be processed by Prc  
(268–270). In actuality PBP3SAL itself has only recently been characterized and 
shown to be important for S. Typhimuriums ability to grow within host cells, both in 
fibroblasts and macrophages (281). The production of PBP3SAL is initiated only at low 
pH corresponding to the intracellular acidity of vacuoles, for example in 
macrophages as described in the literature review. Also, PBP3SAL has been 
suggested to take over from PBP3 in the divisome during these intracellular 
conditions (281,282). In addition PBP3SAL has been shown to have a lower affinity for 
β-lactam antibiotics compared to PBP3 resulting in Salmonella populations not being 
able to regrow in β-lactam treated mouse models if the bacterium is lacking pbp3sal 
(283). 
To continue studying whether the lack of prc had an effect beyond the cell culture 
experimentation we moved on to a more complex infection model where BALB/c 
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mice were infected in the form of competitive infections. In this the Δprc-mutant was 
significantly outcompeted by wild-type when recovering the bacteria from liver, 
spleen and gall bladder, indicating that Prc is needed during a whole animal 
infection. As with the cell culture experiments using RAW264.7 cells the additional 
removal of pbp3sal from the Δprc-mutant suppressed this competitive disadvantage 
resulting from the Δprc-mutation by showing that the ΔprcΔpbp3sal-mutant could be 
recovered from the mice at similar proportions to wild-type.   
These results add to the fact established in Paper I where MepS is connected to Prc 
by now also possibly adding PBP3sal into the repertoire of protein partners to Prc. 
Interestingly both MepS and PBP3sal are involved in cell wall metabolism, with 
MepS cleaving the cell wall and PBP3sal synthesizing it. Other proteins involved in 
cell wall metabolism, such as PBP7 and transglycosylase MltG, have also been 
established as possible targets for Prc, albeit not shown in Salmonella but in E. coli 
(271,272,284). This would indicate that Prc and its proteolytic capability probably has 
a regulatory function for various aspects of the cell wall synthesis apparatus, now 
also shown to be involved in infection relevant setting as we show in Paper II.  
5.3 Paper III 
Having described new genetic determinants for Salmonella to be able to proliferate 
within macrophages, Paper III approaches the question on how Salmonella is able to 
get as far as to start proliferating within macrophages. In this we studied how iNOS, 
the enzyme tasked with producing nitric oxide employed in bacteria killing, works on 
the level of individual macrophages during a Salmonella infection. The reason to 
study this aspect of iNOS was due to claims that Salmonella inhibits iNOS via a SPI-
2 dependent mechanism (216). However, as of today there are no studies showing 
how Salmonella does this happens and no effector proteins being translocated by 
the T3SS-2 from SPI-2 have been shown mechanistically to inhibit iNOS, as 
described in the literature review section. 
Paper III begins by trying to establish whether, and to what extent, hypoxia would 
occur in individual RAW264.7 cells infected with Salmonella. The interest in studying 
hypoxia in concert with innate immunity is due to iNOS requiring molecular oxygen to 
for synthesis of nitric oxide (285,286) and due to hypoxia inducing iNOS expression 
via HIF-1α (287). In this we noted that infection indeed generated hypoxia, but with 
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hypoxia not establishing uniformly in the macrophage population. Rather hypoxia 
correlated with the load of intracellular bacteria and in contrast, and contrary to our 
expectation, the hypoxic cells containing Salmonella appeared negative for presence 
of iNOS.  
This data might strengthen the fact that SPI-2 could be involved in inhibiting iNOS in 
the infected cell, as we would expect the intracellular Salmonella in our studies to 
express SPI-2 even though we don't present this data in Paper III. However, we saw 
that iNOS induction in RAW264.7 cells did not require living Salmonella to be 
present, but instead simply that presence of lipopolysaccharide or peptidoglycan was 
enough to activate iNOS production. Yet, the induction of iNOS in the RAW264.7 
cells was concentration dependent only up to a point, with approximately 70% of the 
RAW264.7 cells not producing iNOS regardless of how much TLR-ligand was 
provided.  
As the presence of Salmonella infection in individual RAW264.7 cells correlated with 
hypoxia, but not with iNOS, the question remained as to what the reason for both of 
these correlations could be. For this we asked whether the lack of iNOS might 
actually not be a direct inhibition by Salmonella on iNOS or iNOS expression, but 
instead an indirect effect. This indirect effect could be due to a general effect of 
Salmonella infection on protein synthesis of the macrophage imposed by the 
immense metabolic burden posed by the proliferating Salmonella. This could mean 
that proliferation of Salmonella would indirectly result in the macrophage not being 
able to defend itself by using iNOS and possibly other means also affected by the 
general lack of protein synthesis. For this we observed that the presence of large 
amounts of Salmonella correlated with the RAW264.7 cell being less active for 
protein synthesis. Moreover, later in the infection almost no cells containing 
Salmonella were actively synthesizing proteins, albeit still alive, indicating that the 
Salmonella infection leads to shut-off of protein synthesis in the infected cell.  
Although SPI-2 has been suggested to affect the localization of iNOS (216), 
suggesting a direct mechanism, the details presented in Paper III leads one to think 
of two possible scenarios for an indirect mechanism. One possible scenario is based 
on the observation that only part of the RAW264.7 cells could be induced to produce 
iNOS, which suggest an inherently heterogenic population. Hence, lack of iNOS in 
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Salmonella infected cells could simply be down to the fact that that specific 
RAW264.7 cell could not mount an iNOS defense from the beginning. The other 
possible scenario we term "the chicken race". This scenario assumes that when 
Salmonella infects a RAW264.7 cell it is a question whether Salmonella is fast 
enough to "outrun" the macrophage defenses to the point that hypoxia is induced 
and hence a broad protein synthesis shut-off that in the end disarms the 
macrophage. This might well be a possibility since hypoxia in general reduces 
protein synthesis mainly due to the lack of ATP generation (288–290), but 
simultaneously confusing due to hypoxia and SPI-1 effectors inducing iNOS 
expression (287,291).  
 
FIGURE 15 A schematic of "the chicken race" hypothesis describing how a Salmonella infection 
possibly proceeds in an individual macrophage in regards to amount of Salmonella, presence of iNOS, 
oxygen status, and level of protein synthesis. 
Yet "the chicken race" might not be a race against iNOS itself, but could be seen 
more as a siege where Salmonella has to hold out for long enough for the 
macrophage to run out of substrate for iNOS in the form of L-arginine, whose 
availability has been correlated with the microbistatic effect of macrophages 
(292,293). Once Salmonella would get an advantage over the macrophage iNOS 
would rapidly vanish, due to its short half-life (294), and the bacteria would be free to 
proliferate. Hence, the response of Salmonella against iNOS during a successful 
infection could be a combination of a SPI-2-mediated direct inhibition of the 
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localization of iNOS (216), RNS detoxifying enzymes (220), and an indirect shut-off 








Salmonella enterica is a species of Gram-negative bacteria causing substantial 
burden on human health worldwide. The diseases Salmonella enterica can cause 
range from gastroenteritis to typhoid fever. Typhoid fever is caused by S. Typhi and 
is the most severe form of the diseases in that it results in the systematic 
dissemination of the bacterium throughout the body with organs such as liver, 
spleen, and bone marrow affected. This is accompanied with high mortality, 
especially for children, and made worse due to the rapidly developing antibiotic 
resistance. Yet S. Typhi does not cause acute gastroenteritis, which instead is a 
characteristic of human infections due to S. Typhimurium. Curiously, when infecting 
mice with S. Typhimurium a typhoid fever-like illness manifests allowing S. 
Typhimurium to be used as a model organism.  
By studying the intrinsic antibiotic resistance of S. Typhimurium towards the cell wall 
synthesis inhibitor vancomycin in Paper I we begin to highlight new aspects of this 
form of antibiotic resistance. Previously vancomycin resistance in Gram-negative 
enteric bacteria was thought to be due to the antibiotic not being able to pass the 
outer membrane. However, in Paper I we show that this intrinsic resistance does not 
solely rely on the outer membrane, but that there also is a contribution from the 
muramyl endopeptidase MepS, a cell wall cleaving enzyme. We also show that this 
contribution is most likely due to MepS stabilizing the autolytic system and is 
dependent on the periplasmic protease Prc (also known as Tsp). By these results we 
add to the knowledge of determinants for antibiotic resistance towards a specific 
antibiotic. 
In Paper II we move on from antibiotic resistance to intracellular pathogenesis. In this 
we show that Prc is needed for full fitness of S. Typhimurium in both macrophages 
and mice. This we suggest is due to the Salmonellas lesser ability to proliferate 
within host cells when lacking prc. Surprisingly, this attribute of Prc is not dependent 
on MepS, as could be hypothesized due to literature and observations made in 
Paper I, but instead is dependent on peptidoglycan synthase PBP3SAL,  a protein 
recently shown to aid S. Typhimurium in proliferating within host cells. These results 
suggest that the pool of targets for the periplasmic protease Prc contains even more 
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proteins involved in cell wall synthesis than previously shown highlighting the 
importance of the regulatory potential of this protease. 
As for the ability of S. Typhimurium to proliferate within macrophages we show in 
Paper III that the presence of S. Typhimurium in said macrophages correlates with 
presence of hypoxia and absence of the innate immunity effector iNOS, an enzyme 
producing RNS tasked with killing the bacteria. We hypothesize that the lack of iNOS 
might be due to an indirect effect by hypoxia leading to shut-off of protein synthesis, 
thus allowing for S. Typhimurium to proliferate within the cells. These results could 
implicate that some of the effects of SPI-2 could be indirect through the ability of the 





7 POINTS OF PERSPECTIVE 
This thesis presents work relying heavily on molecular biology techniques in order to 
try to understand fundamental biological aspects of Salmonella. This lends the 
research performed in this thesis to the option of further experimentation as there are 
always ways in which one can go deeper into the study questions by using anything 
from very sophisticated genetic manipulation to omics-based data collections. One 
such avenue of future research that can be applied to this thesis is to find out more 
exact mechanistic details of the biology that has been studied. Even though we 
haven't managed to give definitive answers on said mechanical details we still 
believe our contribution is valuable to the field and hope others will build upon our 
work.  
In Paper I specific details that could be answered in the future are for example how 
MepS actually contributes to the intrinsic vancomycin resistance in S. Typhimurium. 
We suggest that MepS is involved in stabilizing the autolytic system, but are not able 
to present exactly how this happens. To give specific details of MepS's involvement 
is of course not a simple task already due to the fact that one in general doesn't 
know how the autolytic system works. Additionally, it is counterintuitive that a 
catalytically active MepS is needed for the phenotype as this would mean that the 
bacteria needs an enzyme that cleaves cell wall in order to stabilize an autolytic 
process that when initiated results in cleavage of the cell wall.  
As for Paper II the question remains in what the mechanistic relationship between 
Prc and PBP3SAL is. To begin answering this one could by in vitro experimentation 
show whether Prc degrades/processes PBP3SAL in a similar fashion that Prc 
degrades MepS and processes PBP3. This aspect could then be extended to in vivo 
by attempting to show degradation or processing of PBP3SAL in the absence and 
presence of Prc in cell culture or mouse infection experiments. However, this would 
be complicated since the level of expression of PBP3SAL is at best low leading to 
detection of PBP3SAL being difficult in such experiments.  
As for Paper III we show that S. Typhimurium infection of individual macrophages 
correlates with hypoxia and lack of iNOS. However, we do not definitively show is 
how these are mechanistically couple to each other. One possibly could be due to 
lack of protein synthesis in the macrophage resulting in the lack of iNOS when S. 
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Typhimurium is present. This would require experimentation establishing many parts 
of the correlations all from how Salmonella infection results in hypoxia to how this 
hypoxia would lead to shut-off of protein synthesis. Additionally one could consider 
measuring nitric oxide levels, possibly via indirect means through reporter-fusions, 
within macrophages as the presence of iNOS in slightly hypoxic Salmonella infected 
cells might not necessary mean that the enzyme is catalytically active due to 
substrate unavailability. This way the temporal relationship between hypoxia, iNOS, 
and Salmonella within a RAW264.7 cell could be strengthened and possibly 
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